- Home
- CJET vs NEUP Comparison
CJET vs NEUP Comparison
Compare CJET & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- NEUP
- Stock Information
- Founded
- CJET 2009
- NEUP 1996
- Country
- CJET China
- NEUP United States
- Employees
- CJET N/A
- NEUP N/A
- Industry
- CJET Auto Manufacturing
- NEUP
- Sector
- CJET Consumer Discretionary
- NEUP
- Exchange
- CJET Nasdaq
- NEUP Nasdaq
- Market Cap
- CJET 8.3M
- NEUP 9.3M
- IPO Year
- CJET N/A
- NEUP N/A
- Fundamental
- Price
- CJET $2.02
- NEUP $4.74
- Analyst Decision
- CJET
- NEUP Strong Buy
- Analyst Count
- CJET 0
- NEUP 1
- Target Price
- CJET N/A
- NEUP $21.00
- AVG Volume (30 Days)
- CJET 57.6K
- NEUP 10.9K
- Earning Date
- CJET 06-26-2025
- NEUP 05-23-2025
- Dividend Yield
- CJET N/A
- NEUP N/A
- EPS Growth
- CJET N/A
- NEUP N/A
- EPS
- CJET N/A
- NEUP N/A
- Revenue
- CJET $10,275,000.00
- NEUP $662,715.00
- Revenue This Year
- CJET N/A
- NEUP N/A
- Revenue Next Year
- CJET N/A
- NEUP N/A
- P/E Ratio
- CJET N/A
- NEUP N/A
- Revenue Growth
- CJET 31.31
- NEUP N/A
- 52 Week Low
- CJET $1.09
- NEUP $2.12
- 52 Week High
- CJET $23.94
- NEUP $15.24
- Technical
- Relative Strength Index (RSI)
- CJET 54.40
- NEUP N/A
- Support Level
- CJET $1.69
- NEUP N/A
- Resistance Level
- CJET $2.44
- NEUP N/A
- Average True Range (ATR)
- CJET 0.25
- NEUP 0.00
- MACD
- CJET 0.01
- NEUP 0.00
- Stochastic Oscillator
- CJET 45.45
- NEUP 0.00
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.